"Jan. 29, 2013 -- Older women with heart problems may be at greater risk for mental changes that are thought to signal the beginnings of a type of dementia, a new study shows.
Called vascular dementia, it is a type of mental decline that"...
(Generic versions may still be available.)
IV Persantine® (dipyridamole USP) is indicated as an alternative to exercise in thallium myocardial perfusion imaging for the evaluation of coronary artery disease in patients who cannot exercise adequately.
In a study of about 1100 patients who underwent coronary arteriography and IV Persantine® assisted thallium imaging, the results of both tests were interpreted blindly and the sensitivity and specificity of the Persantine® thallium study in predicting the angiographic outcome were calculated. The sensitivity of the Persantine® test (true positive Persantine® divided by the total number of patients with positive angiography) was about 85%. The specificity (true negative divided by the number of patients with negative angiograms) was about 50%. In a subset of patients who had exercise thallium imaging as well as Persantine® thallium imaging, sensitivity and specificity of the two tests was almost identical.
DOSAGE AND ADMINISTRATION
The dose of intravenous Persantine® (dipyridamole USP) as an adjunct to thallium myocardial perfusion imaging should be adjusted according to the weight of the patient. The recommended dose is 0.142 mg/kg/minute (0.57 mg/kg total) infused over 4 minutes. Although the maximum tolerated dose has not been determined, clinical experience suggests that a total dose beyond 60 mg is not needed for any patient. Prior to intravenous administration, IV Persantine® should be diluted in at least a 1:2 ratio with 0.45% sodium chloride injection, 0.9% sodium chloride injection, or 5% dextrose injection for a total volume of approximately 20 to 50 mL. Infusion of undiluted Persantine® may cause local irritation. Thallium-201 should be injected within 5 minutes following the 4-minute infusion of Persantine®.
Do not mix IV Persantine® with other drugs in the same syringe or infusion container.
Parenteral drug product should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
IV Persantine® (dipyridamole USP) for intravenous injection is available in boxes of five, ten and twenty vials. Each 10 mL vial contains 50 mg of dipyridamole, NDC number 11994-005-05, 11994-005-10, 11994-005-20.
Store at 25°C (77°F); excursions permitted to 15-30°C (59°-86°F). [see USP Controlled Room Temperature]. Protect from direct light. Avoid freezing.
Medical Imaging, Inc.
Rev 7 Jan 2002
Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.
Additional Persantine IV Information
- Persantine IV Drug Interactions Center: dipyridamole iv
- Persantine IV Side Effects Center
- Persantine IV Overview including Precautions
- Persantine IV FDA Approved Prescribing Information including Dosage
Persantine IV - User Reviews
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.